CSCO breast cancer management guidelines 2022: Australian perspective.
作者信息
Yong Chen Han, Gupta Anurag, Joshi Rohit
机构信息
Department of Medical Oncology, Lyell McEwin Hospital, Adelaide, South Australia, Australia.
Department of Breast & Endocrine Surgery, Lyell McEwin and Modbury Hospitals, Adelaide, South Australia, Australia.
出版信息
Transl Breast Cancer Res. 2022 Oct 31;3:36. doi: 10.21037/tbcr-22-46. eCollection 2022.
Abstract
摘要
相似文献
1
CSCO breast cancer management guidelines 2022: Australian perspective.
Transl Breast Cancer Res. 2022 Oct 31;3:36. doi: 10.21037/tbcr-22-46. eCollection 2022.
2
Chinese Society of Clinical Oncology (CSCO) Breast Cancer Guidelines 2022.
Transl Breast Cancer Res. 2022 Apr 30;3:13. doi: 10.21037/tbcr-22-21. eCollection 2022.
3
Consistency of CSCO AI with Multidisciplinary Clinical Decision-Making Teams in Breast Cancer: A Retrospective Study.
Breast Cancer (Dove Med Press). 2024 Jul 29;16:413-422. doi: 10.2147/BCTT.S419433. eCollection 2024.
4
A comparison between clinical decision support system and clinicians in breast cancer.
Heliyon. 2023 May 5;9(5):e16059. doi: 10.1016/j.heliyon.2023.e16059. eCollection 2023 May.
5
Chinese Society of Clinical Oncology (CSCO) Breast Cancer guidelines 2024.
Transl Breast Cancer Res. 2024 Jul 25;5:18. doi: 10.21037/tbcr-24-31. eCollection 2024.
6
Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with early breast cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOS.
Ann Oncol. 2020 Apr;31(4):451-469. doi: 10.1016/j.annonc.2020.01.008. Epub 2020 Jan 16.
7
The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2021.
Cancer Commun (Lond). 2021 Aug;41(8):747-795. doi: 10.1002/cac2.12193. Epub 2021 Jul 1.
8
The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2023.
Cancer Commun (Lond). 2024 Jan;44(1):127-172. doi: 10.1002/cac2.12516. Epub 2023 Dec 31.
9
A comparison of ClearSight noninvasive cardiac output and pulmonary artery bolus thermodilution cardiac output in cardiac surgery patients.
Perioper Med (Lond). 2022 Jun 9;11(1):24. doi: 10.1186/s13741-022-00248-1.
10
The Chinese Society of Clinical Oncology (CSCO) clinical guidelines for the diagnosis and treatment of nasopharyngeal carcinoma.
Cancer Commun (Lond). 2021 Nov;41(11):1195-1227. doi: 10.1002/cac2.12218. Epub 2021 Oct 26.
本文引用的文献
1
Chinese Society of Clinical Oncology (CSCO) Breast Cancer Guidelines 2022.
Transl Breast Cancer Res. 2022 Apr 30;3:13. doi: 10.21037/tbcr-22-21. eCollection 2022.
2
The impact of anthracyclines in intermediate and high-risk HER2-negative early breast cancer-a pooled analysis of the randomised clinical trials PlanB and SUCCESS C.
Br J Cancer. 2022 Jun;126(12):1715-1724. doi: 10.1038/s41416-021-01690-6. Epub 2022 Feb 22.
3
Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03).
J Clin Oncol. 2022 Jan 20;40(3):282-293. doi: 10.1200/JCO.21.02554. Epub 2021 Dec 7.
4
Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer-The Penelope-B Trial.
J Clin Oncol. 2021 May 10;39(14):1518-1530. doi: 10.1200/JCO.20.03639. Epub 2021 Apr 1.
5
Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-Up.
J Clin Oncol. 2021 May 1;39(13):1448-1457. doi: 10.1200/JCO.20.01204. Epub 2021 Feb 4.
6
Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE).
J Clin Oncol. 2020 Dec 1;38(34):3987-3998. doi: 10.1200/JCO.20.02514. Epub 2020 Sep 20.
7
Pembrolizumab for Early Triple-Negative Breast Cancer.
N Engl J Med. 2020 Feb 27;382(9):810-821. doi: 10.1056/NEJMoa1910549.
8
Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer.
N Engl J Med. 2019 Feb 14;380(7):617-628. doi: 10.1056/NEJMoa1814017. Epub 2018 Dec 5.
9
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet Oncol. 2017 Dec;18(12):1688-1700. doi: 10.1016/S1470-2045(17)30717-9. Epub 2017 Nov 13.
10
Anthracyclines in Early Breast Cancer: The ABC Trials-USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology).
J Clin Oncol. 2017 Aug 10;35(23):2647-2655. doi: 10.1200/JCO.2016.71.4147. Epub 2017 Apr 11.
Zotero 插件